KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Non Operating Income (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Non Operating Income data on record, last reported at $12.1 million in Q4 2025.

  • For Q4 2025, Non Operating Income rose 153.29% year-over-year to $12.1 million; the TTM value through Dec 2025 reached -$22.6 million, down 36.66%, while the annual FY2025 figure was -$22.6 million, 36.66% down from the prior year.
  • Non Operating Income reached $12.1 million in Q4 2025 per CRL's latest filing, up from -$22.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $115.5 million in Q4 2022 and bottomed at -$39.8 million in Q2 2022.
  • Average Non Operating Income over 5 years is $2.6 million, with a median of -$3.0 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: skyrocketed 5476.59% in 2022, then plummeted 972.61% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $2.1 million in 2021, then surged by 5476.59% to $115.5 million in 2022, then fell by 6.76% to $107.7 million in 2023, then crashed by 121.07% to -$22.7 million in 2024, then soared by 153.29% to $12.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $12.1 million in Q4 2025, -$22.6 million in Q3 2025, and $154000.0 in Q2 2025.